The FDA approved Latisse, the first drug to promote eyelash growth, according to Allergan, the company that makes Latisse.
Latisse became available by prescription starting in the first quarter of 2009. Latisse contains the active ingredient of the glaucoma drug Lumigan, which is also made by Allergan.
Eyelash growth is a known side effect of Lumigan. But Lumigan and Latisse are used differently. Lumigan is an eyedrop, and Latisse gets dabbed along the lash line on the upper eyelids to promote longer, thicker, darker lashes.
Allergan states that "Latisse users can expect to experience longer, fuller, and darker eyelashes in as little as eight weeks, with full results in 16 weeks." If Latisse is stopped, eyelashes will gradually return to their previous appearance as new eyelashes grow in.
According to Allergan, Latisse was well-tolerated in its clinical trials, with the most common side effects being eye redness, itchy eyes, and skin hyperpigmentation.
Call us today at 360.892.0096 ext. 2 to make an appointment today!